With the latest report on fertility treatment add-ons from the ESHRE revealing that clinics are implementing treatments with an unproven success rate into their care plans, Bridge Clinic London is calling for greater financial transparency in order to protect patients’ best interests.
EMA committee recommends approvals for Lilly’s weight loss drug, Mirati’s KRAS inhibitor and more
The European Medicines Agency’s human medicines committee (CHMP) this week gave a thumbs-up to nine label expansions and eight new drugs, including Eli Lilly’s tirzepatide